Oncolys BioPharma Inc. Logo

Oncolys BioPharma Inc.

Develops oncolytic virus therapies and diagnostics for cancer treatment.

4588 | T

Overview

Corporate Details

ISIN(s):
JP3202170001
LEI:
Country:
Japan
Address:
港区虎ノ門4−1−28虎ノ門タワーズオフィス10階

Description

Oncolys BioPharma Inc. is a biopharmaceutical company focused on the research and development of breakthrough therapies and diagnostics for cancer. The company's core technology is oncolytic virotherapy, which utilizes viruses to selectively target and destroy cancer cells. Its development pipeline addresses multiple stages of cancer care, spanning from early detection and prognostic testing to loco-regional and systemic treatments. The company aims to develop innovative and effective drugs to meet the needs of patients and healthcare providers in the field of oncology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2021-03-26 05:11
有価証券報告書-第17期(令和2年1月1日-令和2年12月31日)
Japanese 1.3 MB
2020-11-06 07:07
四半期報告書-第17期第3四半期(令和2年7月1日-令和2年9月30日)
Japanese 444.5 KB
2020-08-07 08:15
四半期報告書-第17期第2四半期(令和2年4月1日-令和2年6月30日)
Japanese 470.1 KB
2020-05-08 08:15
四半期報告書-第17期第1四半期(令和2年1月1日-令和2年3月31日)
Japanese 183.8 KB
2020-03-27 05:45
有価証券報告書-第16期(平成31年1月1日-令和1年12月31日)
Japanese 1.3 MB
2019-11-05 08:39
四半期報告書-第16期第3四半期(2019/07/01-2019/09/30)
Japanese 343.7 KB
2019-08-09 09:10
四半期報告書-第16期第2四半期(2019/04/01-2019/06/30)
Japanese 368.3 KB
2019-05-10 09:13
四半期報告書-第16期第1四半期(2019/01/01-2019/03/31)
Japanese 177.7 KB
2019-04-05 06:32
訂正有価証券報告書-第15期(平成30年1月1日-平成30年12月31日)
Japanese 617.1 KB
2019-04-05 06:23
訂正四半期報告書-第15期第3四半期(2018/07/01-2018/09/30)
Japanese 135.5 KB
2019-04-05 06:13
訂正有価証券報告書-第14期(平成29年1月1日-平成29年12月31日)
Japanese 646.3 KB
2019-04-05 03:37
訂正四半期報告書-第14期第3四半期(2017/07/01-2017/09/30)
Japanese 112.4 KB
2019-04-05 03:30
訂正四半期報告書-第14期第2四半期(2017/04/01-2017/06/30)
Japanese 140.0 KB
2019-04-05 03:23
訂正四半期報告書-第14期第1四半期(2017/01/01-2017/03/31)
Japanese 110.3 KB
2019-04-05 03:09
訂正有価証券報告書-第13期(2016/01/01-2016/12/31)
Japanese 797.8 KB

Automate Your Workflow. Get a real-time feed of all Oncolys BioPharma Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Oncolys BioPharma Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Oncolys BioPharma Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.